Market research
STAR.NSE Strides Pharma Science Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 91B
- P/E ratio
- 14.82
- Analyst target
- 1338.6666
- Dividend yield
- 0.0%
- Beta
- 0.39
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE939A01011
- Market cap
- 91B
- P/E ratio
- 14.82
- Analyst target
- 1338.6666
- Dividend yield
- 0.0%
- Beta
- 0.39
About
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasalsprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the STAR.NSE discussion.
5 years, 4 months ago
Strides Pharma Science Limited is currently in a long term downtrend where the price is trading 4.4% below its 200 day moving average.
From a valuation standpoint, the stock is 47.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Strides Pharma Science Limited's total revenue rose by 13.6% to $8B since the same quarter in the previous year.
Its net income has dropped by 59.7% to $378M since the same quarter in the previous year.
Based on the above factors, Strides Pharma Science Limited gets an overall score of 2/5.